Credit Suisse Maintains Outperform on Ikena Oncology, Lowers Price Target to $27

Credit Suisse maintains Ikena Oncology (NASDAQ:IKNA) with a Outperform and lowers the price target from $30 to $27.

Credit Suisse maintains Ikena Oncology (NASDAQ:IKNA) with a Outperform and lowers the price target from $30 to $27.

Total
0
Shares
Related Posts